Cargando…

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin

AIMS: Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubayashi, Yasuhiro, Yoshida, Akihiro, Suganami, Hideki, Osawa, Taeko, Furukawa, Kazuo, Suzuki, Hiroshi, Fujihara, Kazuya, Tanaka, Shiro, Kaku, Kohei, Sone, Hirohito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318197/
https://www.ncbi.nlm.nih.gov/pubmed/31984623
http://dx.doi.org/10.1111/dom.13980
_version_ 1783550791027523584
author Matsubayashi, Yasuhiro
Yoshida, Akihiro
Suganami, Hideki
Osawa, Taeko
Furukawa, Kazuo
Suzuki, Hiroshi
Fujihara, Kazuya
Tanaka, Shiro
Kaku, Kohei
Sone, Hirohito
author_facet Matsubayashi, Yasuhiro
Yoshida, Akihiro
Suganami, Hideki
Osawa, Taeko
Furukawa, Kazuo
Suzuki, Hiroshi
Fujihara, Kazuya
Tanaka, Shiro
Kaku, Kohei
Sone, Hirohito
author_sort Matsubayashi, Yasuhiro
collection PubMed
description AIMS: Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However, there are few reports of the influence of SGLT2‐is on hepatic insulin clearance. We examined the impact of an SGLT2‐i on hepatic insulin clearance and explored the clinical influence associated with changes in hepatic insulin clearance via an SGLT2‐i and the mechanism of the effects of SGLT2‐i. MATERIALS AND METHODS: Data were analysed from 419 patients with type 2 diabetes controlled by diet and exercise. Patients received a placebo or the SGLT2‐i tofogliflozin (TOFO) (placebo: n = 56; TOFO: n = 363) orally once daily for ≥24 weeks. Hepatic insulin clearance was calculated from the ratio of areas under the curve (AUC) of C‐peptide and insulin levels derived from oral meal tolerance test data (C‐peptide AUC(0‐120 min)/insulin AUC(0‐120 min): HIC(CIR)). The correlation of HIC(CIR) via the SGLT2‐i with other clinical variables was analysed using multivariate analysis. RESULTS: HIC(CIR) was significantly increased via TOFO at week 24. Furthermore, with TOFO insulin and triglyceride (TG) levels were significantly reduced (P < 0.001) and β‐hydroxybutyrate (BHB) was significantly elevated (P < 0.001). Changes in HIC(CIR) were significantly correlated with changes in TG and BHB via TOFO. CONCLUSIONS: Increased HIC(CIR) was significantly associated with reduced TG via TOFO and contributed to the greater increase in BHB compared with placebo in addition to the correction of hyperinsulinaemia.
format Online
Article
Text
id pubmed-7318197
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-73181972020-06-29 Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin Matsubayashi, Yasuhiro Yoshida, Akihiro Suganami, Hideki Osawa, Taeko Furukawa, Kazuo Suzuki, Hiroshi Fujihara, Kazuya Tanaka, Shiro Kaku, Kohei Sone, Hirohito Diabetes Obes Metab Original Articles AIMS: Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However, there are few reports of the influence of SGLT2‐is on hepatic insulin clearance. We examined the impact of an SGLT2‐i on hepatic insulin clearance and explored the clinical influence associated with changes in hepatic insulin clearance via an SGLT2‐i and the mechanism of the effects of SGLT2‐i. MATERIALS AND METHODS: Data were analysed from 419 patients with type 2 diabetes controlled by diet and exercise. Patients received a placebo or the SGLT2‐i tofogliflozin (TOFO) (placebo: n = 56; TOFO: n = 363) orally once daily for ≥24 weeks. Hepatic insulin clearance was calculated from the ratio of areas under the curve (AUC) of C‐peptide and insulin levels derived from oral meal tolerance test data (C‐peptide AUC(0‐120 min)/insulin AUC(0‐120 min): HIC(CIR)). The correlation of HIC(CIR) via the SGLT2‐i with other clinical variables was analysed using multivariate analysis. RESULTS: HIC(CIR) was significantly increased via TOFO at week 24. Furthermore, with TOFO insulin and triglyceride (TG) levels were significantly reduced (P < 0.001) and β‐hydroxybutyrate (BHB) was significantly elevated (P < 0.001). Changes in HIC(CIR) were significantly correlated with changes in TG and BHB via TOFO. CONCLUSIONS: Increased HIC(CIR) was significantly associated with reduced TG via TOFO and contributed to the greater increase in BHB compared with placebo in addition to the correction of hyperinsulinaemia. Blackwell Publishing Ltd 2020-02-14 2020-06 /pmc/articles/PMC7318197/ /pubmed/31984623 http://dx.doi.org/10.1111/dom.13980 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Matsubayashi, Yasuhiro
Yoshida, Akihiro
Suganami, Hideki
Osawa, Taeko
Furukawa, Kazuo
Suzuki, Hiroshi
Fujihara, Kazuya
Tanaka, Shiro
Kaku, Kohei
Sone, Hirohito
Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
title Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
title_full Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
title_fullStr Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
title_full_unstemmed Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
title_short Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
title_sort association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318197/
https://www.ncbi.nlm.nih.gov/pubmed/31984623
http://dx.doi.org/10.1111/dom.13980
work_keys_str_mv AT matsubayashiyasuhiro associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT yoshidaakihiro associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT suganamihideki associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT osawataeko associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT furukawakazuo associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT suzukihiroshi associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT fujiharakazuya associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT tanakashiro associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT kakukohei associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin
AT sonehirohito associationofincreasedhepaticinsulinclearanceandchangeinserumtriglyceridesorbhydroxybutyrateconcentrationviathesodiumglucosecotransporter2inhibitortofogliflozin